This year’s show, taking place in Frankfurt, Germany, has grown further incorporating representation from the whole bio/pharma supply chain and providing networking opportunities for a global audience, reveals Tara Dougal, Event Director.

According to Kevin Li from BioDuro, bio/pharma partnerships are most successful when the parties involved are aligned, operating as one team with mutual trust and long-term vision.

It is possible to achieve longer-acting injectable drug products that also do not require aseptic fill/finish thanks to a new advanced drug delivery system, reveals Mårten Rooth from Nanexa.

While widespread adoption of 3D printing within the bio/pharma industry needs to overcome some key hurdles, its potential for the future is tremendous, emphasizes Tom Sellig from Adare Pharma Solutions.

Bio/pharma companies are turning their focus to Indian CDMOs to build resilience into their KSM and API supply chains and to help with complex payloads, according to Yann D’Hervé from Cohance.

Bio/pharma companies are adjusting their strategies to cope with a variety of industry trends and are seeking out partners that can not only provide them with capacity but also support them through their innovation journey.

As demand for increasingly complex biologics grows, technological advances and innovative approaches are enabling companies to progress their biomanufacturing efforts.

With an increasing spotlight on sustainability, it is increasingly important for industry-wide sustainability practices to be implemented to ensure transformative change is achieved.

While biomanufacturing has ample capacity, a funding downturn and workforce shortages have created a paradoxical situation, putting pressure on sponsors’ decisions when it comes to choosing their manufacturing partners.

While there have been promising advances in terms of technologies to help the development and manufacture of next-gen therapies, limitations remain; but, it is likely that AI will be revolutionary for development in the near future.

Advanced technologies, while important for the successful development and manufacture of next-gen therapies, are still a long way off being impactful, meaning more investment is needed to reap the rewards of these promising treatments.

Digital systems, automation, and flexibility are crucial for overcoming the hurdles associated with the development and manufacture of next-gen therapies, but ongoing investment is critical to ensure continued innovation in the sector.

Affordability and accessibility are critical factors for commercial success of next-gen therapies; however, greater industry collaboration is needed to reduce inefficiencies in the development of advanced technologies.

In this interview, David Phasey from 3P innovation highlights why advanced technologies are critical to helping companies overcome the challenges associated with the development and manufacture of next-generation therapies.

Despite the numerous challenges facing the development, manufacture, and commercialization of next-generation therapies, the end value proposition they offer is significant and worth the effort from stakeholders.

With digitalization gaining traction in biomanufacturing, The Pharma Navigator speaks to experts about how digital twins and advanced modeling are helping companies meet industry demands and what that means for the workforce.

While meaningful progress has been made by the biopharmaceutical industry into digitalization, there is still a lot of work to do to achieve a true digital transformation.

Strategic early planning, optimal CDMO selection, careful scale management, and stringent quality, along with greater industry collaboration, will ensure future biomanufacturing success.

As the complexity of drug molecules evolve and patient expectations grow, industry leaders reveal why the next generation of drug delivery must balance cutting-edge science, flexible manufacturing, and patient-centric design.

With a grant of £1 million from Innovate UK, Cellular Origins, the CGT Catapult, and Resolution Therapeutics will work together to create a fully automated, scalable cell therapy manufacturing platform.